Objectives: We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.

Trial Design: This is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.

Participants: Inclusion criteria: 1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran 2. Age ≥18 years (weight ≥35 kg) 3. Hospitalized ≤48 hours 4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PCR)) 5. Moderate pneumonia and lung involvement in imaging 6. Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm Exclusion criteria: 1. Underlying diseases, including heart disease, chronic hypertension, severe renal failure, severe liver failure, and thyroid disorders 2. Use of warfarin, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), diuretics, corticosteroids, and antiarrhythmic drugs 3. Severe and critical pneumonia 4. History of known allergy to Ginger 5. Pregnancy and breastfeeding INTERVENTION AND COMPARATOR: Intervention group: The standard treatment regimen for COVID-19 along with Ginger-based herbal tablets (Vomigone ®, Dineh Pharmaceutical Company, Iran) at a dose of 1000 mg three times a day for a period of seven days.

Control Group: The standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education's protocol, along with Vomigone-like placebo tablets (Dineh Pharmaceutical Company, Iran) at a dose of two tablets three times a day for a period of seven days.

Main Outcomes: The primary outcome is recovery rate of clinical symptoms, including fever, dry cough, tiredness, and GI symptoms as well as paraclinical features, including thrombocytopenia, lymphocytopenia, and C-reactive protein within seven days of randomization. Time to improvement of clinical and paraclinical features along with the incidence of serious adverse events are the secondary outcomes within seven days of randomization.

Randomization: An interactive web-based system will be used to allocate eligible participants, based on the inclusion and exclusion criteria, to one of the two study arms (in a 1:1 ratio) using block randomization.

Blinding (masking): All study participants, research coordinators, clinicians, nurses, and investigators will be blinded to the group assignment.

Numbers To Be Randomized (sample Size): A total of 84 participants will be randomized into two groups of 42 patients.

Trial Status: The protocol is Version 1.0, May 23, 2020. Recruitment began July 21, 2020, and is anticipated to be completed by October 30, 2020.

Trial Registration: This clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20200506047323N1 ". Registration date is 23 May 2020.

Full Protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545374PMC
http://dx.doi.org/10.1186/s13063-020-04765-6DOI Listing

Publication Analysis

Top Keywords

paraclinical features
16
effects ginger
8
clinical manifestations
8
manifestations paraclinical
8
features patients
8
severe acute
8
acute respiratory
8
respiratory syndrome
8
clinical trial
8
exclusion criteria
8

Similar Publications

Background: Neuronal surface antibody-associated autoimmune encephalitis (NSAE) is a group of neuro-inflammatory disorders that is mediated by autoantibodies against the cell-surface and synaptic antigens. Studies have explored the role of neurofilament light chain (NfL) in NSAE and provided inconsistent data. We performed a systematic review and meta-analysis to evaluate the NfL levels in the serum and cerebrospinal fluid (CSF) of patients with NSAE.

View Article and Find Full Text PDF

Objectives: This study describes the clinical and paraclinical features, antibiotic resistance levels, and treatment outcomes of septicemia acquired in the Vietnamese community.

Methods: A cross-sectional descriptive study was conducted on 102 patients with community-acquired sepsis caused by from July 2018 to July 2023.

Results: -induced community sepsis had a septic shock rate of 13.

View Article and Find Full Text PDF

Background: Data regarding long-term recovery from autoimmune encephalitis (AE) remain limited.

Methods: This retrospective observational study investigated outcomes in 182 patients who met the 2016 criteria for definite AE. Recovery data were available in 172 patients.

View Article and Find Full Text PDF

Aims: This study investigates the differences in patient demographics and outcomes between teaching and non-teaching hospitals in Iran. By analyzing these differences, it aims to provide useful information for policymakers to optimize resource allocation, improve patient care, and balance educational and service delivery goals in teaching hospitals.

Materials And Methods: In this cross-sectional investigation, both teaching and non-teaching general hospitals were examined.

View Article and Find Full Text PDF

Chapter 13: Changes in 2022 WHO classification of parathyroid tumors.

Ann Endocrinol (Paris)

January 2025

Institute of Pathology, University of Lille, CHU of Lille, 59000 Lille cedex, France. Electronic address:

The latest 2022 WHO classification of the parathyroid tumors incorporates recent data on parathyroid pathophysiology, in particular from genetic sequencing. It highlights histological features potentially indicative of underlying genetic abnormalities, because of their implications for patient management. Immunohistochemical markers can help characterize parathyroid lesions and molecular screening.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!